Sermorelin dosage for muscle growth: what clinicians actually prescribe. - Reddit

What is sermorelin and why does it matter for body composition?

Sermorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) — a 29-amino-acid fragment of the natural GHRH sequence that retains full biological activity at the pituitary GHRH receptor. When administered subcutaneously, sermorelin binds to pituitary receptors and stimulates the gland to release growth hormone in its natural pulsatile pattern.

This pulsatile mechanism is what distinguishes sermorelin from exogenous growth hormone. Sermorelin does not replace your growth hormone — it signals your pituitary to produce more of its own, on its own schedule. The pituitary retains feedback-loop regulation, which means it responds to physiological signals that would normally inhibit GH excess. This is a meaningful safety distinction.

Growth hormone drives IGF-1 production in the liver, and IGF-1 mediates the downstream effects relevant to body composition: protein synthesis support, preferential fat metabolism, and recovery from training stimulus. The mechanism is indirect but physiologically coherent — and it is why sermorelin is used in physician-supervised protocols for adults whose natural GH output has declined with age.

What dose of sermorelin do clinicians actually prescribe for muscle growth?

In physician-supervised protocols, sermorelin for adult body composition and recovery goals is typically prescribed in the range of 200–500 micrograms (mcg) per dose, administered subcutaneously. Most protocols use once-daily dosing, typically before bed.

Those numbers reflect the doses used in clinical practice, not a guarantee that your clinician will prescribe a number in that range. The actual prescribed dose depends on:

• Baseline IGF-1 levels: A lab measurement of your IGF-1 gives the clinician a baseline. Someone with substantially suppressed IGF-1 and a clinician who has documented GH deficiency may be started at the higher end of the range; someone with normal-range IGF-1 exploring optimization may start lower.
• Age: Pituitary responsiveness to GHRH declines with age. Dose adjustments reflect that reality.
• Body weight and composition: Obesity blunts GH secretion even in response to GHRH stimulation. Protocols for patients with significantly elevated BMI may be structured differently.
• Response to initial dosing: Clinicians review follow-up IGF-1 levels (typically at 4–8 weeks) to assess whether the dose is producing the intended physiological signal and adjust accordingly.

Why is sermorelin dosed before bed for muscle growth?

The recommendation to administer sermorelin before sleep is grounded in circadian endocrinology. Growth hormone is not released continuously — it is released in discrete pulses. The largest and most consistent pulse in adults occurs approximately 60–90 minutes after sleep onset, during slow-wave sleep.

Administering sermorelin before bed means the GHRH signal reaches the pituitary around the time the gland is already primed for its largest natural GH pulse. You’re working with the body’s existing hormonal architecture rather than imposing a signal at an arbitrary time.

Food intake suppresses GH release — elevated insulin blunts GH secretion. Most protocols call for administering sermorelin after a fasting period of 2–3 hours (no large meals before bed) for this reason. Some clinicians also advise against high-carbohydrate meals in the few hours before dosing, though the exact threshold is protocol-specific.

How is a sermorelin dose titrated and monitored over time?

A properly supervised sermorelin protocol is not a fixed dose prescribed once and left unchanged for months. It is a titrated protocol with lab-guided adjustment. Here is what that looks like in practice:

• Starting dose: Clinicians often start at the lower end of the dose range (200–300 mcg) to assess tolerability before escalating.
• Follow-up IGF-1 at 4–8 weeks: The lab result tells the clinician whether the current dose is producing a meaningful physiological response. If IGF-1 has not meaningfully changed, dose may be titrated upward.
• Ongoing monitoring: IGF-1 is typically checked quarterly once a stable dose is established. Staying within a physiological range is important — supraphysiological IGF-1 is not the target.
• Cycle structure: Some protocols use cycling (e.g., five days on, two days off, or monthly breaks) to maintain pituitary receptor sensitivity over the long term. Protocol structure is clinician-determined.

What does the dose alone not determine?

The most common misconception about sermorelin protocols — and peptide therapy generally — is that dosage is the primary variable. It isn’t. Sermorelin supports the conditions for growth hormone release. It does not bypass the variables that determine whether that GH signal translates into muscle accretion or fat metabolism.

The factors that determine whether a sermorelin protocol produces meaningful body composition changes include:

• Resistance training stimulus: GH and IGF-1 support protein synthesis in response to training. Without adequate training stimulus, the anabolic signaling has no substrate to act on. Sermorelin is not a substitute for progressive resistance training.
• Protein intake: Muscle protein synthesis requires adequate dietary protein. Protocols that optimize hormonal signaling but underdeliver on protein are leaving adaptation on the table.
• Sleep quality and duration: Sermorelin is dosed before sleep because GH pulses during slow-wave sleep. Poor sleep architecture (fragmentation, insufficient slow-wave sleep) reduces the physiological context the protocol depends on.
• Baseline hormonal status: GH output interacts with sex hormone levels. Adults with significantly suboptimal testosterone or estrogen may see different results than those with optimized endocrine baselines.
• Timeline expectations: Body composition changes from GHRH-analog protocols are measured in months, not weeks. A 3–6 month timeframe is a realistic minimum for assessing meaningful results.

Where is sermorelin sourced and compounded?

Sermorelin is a Category 1 peptide — it can be legally compounded by licensed 503A pharmacies in the USA with a valid clinician’s prescription. It is not an experimental compound in a gray zone. It has a clinical record extending decades, FDA-recognized status under the 503A compounding framework, and established dosing patterns in the published literature.

At PepScribe, sermorelin is compounded in the USA by licensed 503A pharmacies. No hidden overseas supply chain. Each prescription is issued by a licensed clinician after reviewing your intake, baseline labs, and clinical goals. Ongoing check-ins and lab monitoring are part of the protocol — not optional add-ons.

Frequently asked questions